Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
Pralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation. However, adverse events associated with pralsetinib and selpercatin...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2024-11-01
|
| Col·lecció: | Frontiers in Oncology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1431908/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|